Recent Updates — BBLG

Bone Biologics Corporation held its Annual Meeting of Stockholders on September 28, 2026. Shareholders approved an amendment to the Certificate of Incorporation authorizing the Board to effect a reverse stock split within a range of 1-for-2 to 1-for-10 at its discretion. The company also elected four directors: Bruce Stroever, Siddhesh Angle, Robert Gagnon, and Philip Meikle. Additionally, shareholders ratified executive compensation, approved the appointment of Weinberg & Company as independent auditor, and authorized potential warrant-related share issuances exceeding 20% of outstanding stock to comply with Nasdaq rules. Bone Biologics Corp operates in the biotechnology industry, focusing on developing regenerative medicine therapies.

Bone Biologics Corporation received a notice from Nasdaq indicating it no longer meets the minimum bid price requirement of $1 per share for its common stock. The company has an 180-day compliance period ending March 9, 2027, to regain compliance by maintaining a closing bid price of at least $1 for ten consecutive business days. Failure to comply may result in delisting, though the company intends to seek shareholder approval for a reverse stock split as a potential remedy. Bone Biologics Corporation operates in the biotechnology industry, focusing on regenerative medicine and tissue engineering solutions.

On July 15, 2026, Bone Biologics Corporation postponed its 2026 annual meeting of stockholders from August 11, 2026, to September 28, 2026, at 11:30 a.m. ET. The postponement allows the company to include an additional proposal in its Definitive Proxy Statement and provides stockholders more time to review materials. The new record date for the meeting is August 6, 2026, and the deadline for stockholder submissions of director nominees or proposals is July 26, 2026. Bone Biologics Corporation is a biotechnology company that develops bone graft substitutes.

Bone Biologics Corporation priced a private offering of pre-funded warrants and Series F and G warrants to purchase 2,112,677 shares of common stock at a combined price of $1.419 per warrant. The offering generated approximately $2.7 million in net proceeds, with potential additional gross proceeds of $6 million if all warrants are exercised. Bone Biologics Corporation is a biotechnology company focused on developing bone biologics products.